IL17A and rheumatoid arthritis: While classical biologic agents (monoclonal antibodies or recombinant proteins) targeting IL-17 and IL-23, as well as inhibitors of RORγt, have shown potent efficacy only in some fibrotic diseases such as psoriasis and RA, unfortunately, this potential has not been observed in other diseases, such as uveitis and Cröhn’s disease [101].